Brief: Lianbio Announces Infigratinib Approved Under Special Named Patient Program For The Treatment Of Cholangiocarcinoma In The Pilot Zone Of Hainan Province In China
21/12/2021 12:30
Dec 21 (Reuters) - LianBio LIAN.O :
* LIANBIO ANNOUNCES INFIGRATINIB APPROVED UNDER SPECIAL
NAMED
PATIENT PROGRAM FOR THE TREATMENT OF CHOLANGIOCARCINOMA IN THE
PILOT ZONE OF HAINAN PROVINCE IN CHINA
Source text for Eikon: ID:nGNXT8rBF
Further company coverage: LIAN.O
((reuters.briefs@thomsonreuters.com;))
Recent news on LianBio
See all newsChina's Zeekr prices US IPO at top of range to raise $441 million (updated)
U.S. STOCKS ON THE MOVE-JetBlue Airways, LPL Financial, Nvidia
U.S. STOCKS ON THE MOVE-Bicycle Therapeutics, Molson Coors, LianBio
LianBio completes strategic review, cuts jobs; shares up
Brief: LianBio Announces Completion Of Strategic Review